About Aspire Biopharma Holdings, Inc.
https://aspirebiolabs.comAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.
CEO
Kraig T. Higginson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
CREWE ADVISORS LLC
Shares:813.43K
Value:$47.75K
PROCYON ADVISORS, LLC
Shares:472.66K
Value:$27.75K
VANGUARD GROUP INC
Shares:428.55K
Value:$25.16K
Summary
Showing Top 3 of 26
About Aspire Biopharma Holdings, Inc.
https://aspirebiolabs.comAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.94K ▲ | $1.15M ▲ | $-1.85M ▲ | -95.34K% ▼ | $-0.04 ▲ | $0 ▲ |
| Q2-2025 | $0 | $799.89K ▼ | $-1.98M ▲ | 0% | $-0.04 ▲ | $-1.45M ▲ |
| Q1-2025 | $0 | $15.56M ▲ | $-15.94M ▼ | 0% | $-0.33 ▼ | $-15.65M ▼ |
| Q4-2024 | $0 | $2.52M ▲ | $-11.97M ▼ | 0% | $-0.25 ▼ | $-11.08M ▼ |
| Q3-2024 | $0 | $242.62K | $-243.63K | 0% | $-0.01 | $-242.62K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.95M ▲ | $2.4M ▲ | $13.87M ▲ | $-11.47M ▼ |
| Q2-2025 | $206.23K ▼ | $989.42K ▼ | $10.61M ▲ | $-9.62M ▼ |
| Q1-2025 | $1.35M ▲ | $1.97M ▲ | $8.92M ▲ | $-6.95M ▼ |
| Q4-2024 | $3.63K ▼ | $147.99K ▼ | $1.69M ▲ | $-1.54M ▼ |
| Q3-2024 | $16.54K | $184.04K | $985.63K | $-801.59K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.85M ▲ | $-1.1M ▲ | $0 | $2.85M ▲ | $1.74M ▲ | $-1.1M ▲ |
| Q2-2025 | $-1.98M ▲ | $-1.14M ▲ | $0 | $0 ▼ | $-1.14M ▼ | $-1.14M ▲ |
| Q1-2025 | $-15.94M ▼ | $-1.75M ▼ | $0 | $3.09M ▲ | $1.34M ▲ | $-1.75M ▼ |
| Q4-2024 | $-8.93M ▼ | $479.57K ▲ | $0 ▼ | $-492.48K ▼ | $-12.91K ▼ | $479.57K ▲ |
| Q3-2024 | $-243.63K | $-533.8K | $38.26K | $492.48K | $-3.06K | $-533.8K |
CEO
Kraig T. Higginson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
CREWE ADVISORS LLC
Shares:813.43K
Value:$47.75K
PROCYON ADVISORS, LLC
Shares:472.66K
Value:$27.75K
VANGUARD GROUP INC
Shares:428.55K
Value:$25.16K
Summary
Showing Top 3 of 26